A financial adviser is working with the company to deliberate future plans, including a potential sale to other drugmakers, according to the April 10 report. Janux develops tumor-activated T cell therapies for cancer. Its shares quadrupled this year and has a market value of $2.3 billion, according to Bloomberg.
Janux was founded in 2017 and has four products in early research stages, according to its website.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.